{
    "nct_id": "NCT03034200",
    "official_title": "Phase 2 Study of ONC201 in Neuroendocrine Tumors",
    "inclusion_criteria": "1. \"Subjects must have a unresectable, recurrent, locally advanced, refractory, or metastatic neuroendocrine tumor including pheochromocytoma-paraganglioma (PC-PG), DSRCT, Ewing Sarcoma or PNET, or any neuroendocrine tumor with a catecholamine or dopamine biomarker or autocrine or paracrine dependence on dopamine including cholangiocarcinoma and adrenal cortical carcinoma (ACC).\n2. There is no limit on number of prior therapies.\n3. Age ≥14 years.\n4. Subjects must have normal organ and marrow function as defined below. Studies should be done within 3 weeks prior to enrollment\n\n   * Hemoglobin ≥ 10.0 g/dl\n   * Leukocytes ≥ 1500/mcL\n   * Absolute neutrophil count ≥ 1,000/mcL\n   * Platelet count ≥ 75000/mcL\n   * Total bilirubin within 1.5 x normal institutional limits\n   * AST (SGOT) ≤ 5 X institutional upper limit of normal\n   * ALT (SGPT) ≤ 5 X institutional upper limit of normal\n   * Serum Creatinine <3.0mg/dL\n\n     * 5 1 lesion detectable on CT, MRI, 18FDG PET-CT\n\n6 Subjects must have the ability to understand and the willingness to sign a written informed consent document.\n\n7: Karnofsky or if <16 years old Lansky Play Performance status ≥ 60%\nHealthy volunteers allowed\nMust have minimum age of 14 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}